МАГНІЙ ОРОТАТ ЯК ІНСТРУМЕНТ МОДИФІКАЦІЇ ЗАПАЛЕННЯ ТА ПОЛІПШЕННЯ ФІЗИЧНОЇ ВИТРИВАЛОСТІ У ПАЦІЄНТІВ ПІСЛЯ РЕВАСКУЛЯРИЗАЦІЇ

Coronary artery disease (CAD) and heart failure with mildly reduced ejection fraction (HFmrEF) represent interconnected clinical entities characterized by persistent low-grade systemic inflammation. Even in patients who have undergone complete myocardial revascularization, ongoing inflammatory activity remains a critical driver of adverse cardiovascular events and disease progression.Oblective. To improve the efficacy of treatment of patients with stable CAD and heart failure with mid ranged ejection fraction, who underwent myocardial revascularization by percutaneous coronary interventionMaterial and methods. Study included 62 patients with stable coronary artery disease (CAD) and mid-range left ventricular ejection fraction (LVEF 40–49%) who had undergone complete revascularization. Participants were randomized into two groups. Group 1 (n = 29) received standard pharmacological therapy. Group 2 (n = 33) received standard therapy supplemented with magnesium orotate at a dose of 500 mg twice daily. Treatment duration was 6 months with 3 visits: screening and inclusion, follow-up visit after 3 months, follow-up visit after 6 months. All patients underwent a treadmill stress test using the Bruce or modified Bruce protocol, serum concentrations of Galectin-3 and soluble ST2 (sST2) were measured, inflammatory indices, including (NLR), (SII), (PLR), (SIRI), and (AISI), were calculated.The results. The research revealed that magnesium orotate has shown promise as an adjunct therapy in cardiovascular disease. Over the course of the study, the distance covered during the treadmill test showed a significant upward trend in both groups, with a more pronounced improvement observed among patients receiving magnesium orotate. Markers of systemic inflammation demonstrated a favorable dynamic in both groups, although the reduction was substantially more pronounced among patients receiving magnesium orotate. Biomarkers associated with myocardial remodeling and fibrosis exhibited a downward trend throughout the study period, with more favorable shifts observed in the magnesium orotate group.Conclusions. Given the persistent inflammatory activation in stable CAD with HFmrEF and the need for therapies that improve both biomarker profiles and functional capacity, magnesium orotate is a compelling candidate for investigation. Its dual action on myocardial metabolism and inflammation suggests it could modulate key pathways underlying adverse remodeling while also enhancing exercise performance.